Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - H.C. Wainwright raised its price target on Inventiva SA (NASDAQ:IVA) to $24.00 from $20.00 on Thursday, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for IVA range from $3 to $26, with the stock showing remarkable strength through a 225% return over the past year.
The firm’s updated outlook follows Inventiva’s Analyst Day, which highlighted lanifibranor’s unique position as the only oral, once-daily pan PPAR agonist in late-stage development for MASH (metabolic dysfunction-associated steatohepatitis). While the company maintains a strong liquidity position with a current ratio of 2.96, InvestingPro analysis indicates the company is not expected to be profitable this year.
H.C. Wainwright noted that lanifibranor remains the only agent to achieve both MASH resolution and ≥1 stage fibrosis improvement in a 24-week trial, demonstrating nearly 42% fibrosis improvement compared to 24% with placebo.
The NATIV3 trial has now completed enrollment with nearly 1,000 F2/F3 patients plus approximately 400 exploratory cirrhotics in a 72-week study with a 48-week extension, including about 14% of patients on stable GLP-1 therapy.
H.C. Wainwright revised its penetration and probability of success assumptions for lanifibranor based on its understanding of the MASH landscape, the drug’s emerging profile, and key opinion leader perspectives on the future therapeutic landscape for MASH.
In other recent news, Inventiva has seen a series of notable developments. The company has been the subject of multiple analyst reviews, with Stifel reiterating a Buy rating and a $17.00 price target, emphasizing the unique profile of Inventiva’s lead drug candidate, lanifibranor. H.C. Wainwright also assumed coverage with a Buy rating and a $20.00 price target, noting the FDA’s acceptance of a letter of intent for using liver stiffness measurement as a surrogate endpoint. Guggenheim raised its price target for Inventiva from $9.00 to $13.00, citing increased enthusiasm for the MASH market and the target patient population for lanifibranor. Piper Sandler initiated coverage with an Overweight rating and a $26.00 price target, highlighting the potential of lanifibranor for treating metabolic dysfunction-associated steatohepatitis. Additionally, Inventiva announced leadership changes with Jason Campagna appointed as President of Research and Development and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. Campagna takes over from company co-founder Pierre Broqua, who will now serve as a Scientific Advisor. These developments reflect Inventiva’s ongoing strategic efforts and analyst interest in its drug pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.